On the 7th, FunPep ＜4881＞ announced non-clinical trial data and the scheduled start time of clinical trials for the allergy vaccine (antibody-inducing peptide “FPP004X”) under development.
FPP004X can be expected to have a therapeutic effect by inducing antibody production against IgE (Immunoglobulin E), which causes allergic reactions when bound to allergens such as pollen in the body. The company can alleviate symptoms throughout the season by administering it before pollen scattering, and is proceeding with pharmaceutical development with the aim of providing new treatment options that are highly convenient for patients.
It has been confirmed that anti-IgE antibodies are induced and allergic reactions are suppressed (decrease in number of eosinophils and reduction in number of nasal scrapings) in an OVA-induced allergic rhinitis model using humanized IgE/FCempR1 transgenic mice in non-clinical trials of FPP004x. Currently, the target start period for phase 1 clinical trials is the first quarter of the 2025/12 fiscal year, and non-clinical trials are underway.
